Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5246925 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
Oct, 2012
(11 years ago) | |
US5587497 | ABBVIE | 19-nor-vitamin D compounds |
Dec, 2013
(10 years ago) | |
US5587497 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds |
Jun, 2014
(9 years ago) | |
US5597815 | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jul, 2015
(8 years ago) | |
US5597815 (Pediatric) | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jan, 2016
(8 years ago) | |
US6361758 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
US6136799 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
US6361758 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
US6136799 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 18, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 18, 2023 |
New Indication(I-599) | Jun 29, 2012 |
Orphan Drug Exclusivity(ODE-125) | Oct 18, 2023 |
Market Authorisation Date: 26 May, 2005
Treatment: Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5, which may result in renal osteodystrophy, while avoiding hyperphosphatemia
Dosage: CAPSULE;ORAL; SOLUTION;INTRAVENOUS